Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (241-250 of 290) with videos related to

Pageof 29
Sort By:
Cancer Science|September 25, 2020
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy studyKazutaka Sunami, Kenshi Suzuki, Masaki Ri, et al.
Cancer Science|February 26, 2016
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II studyKenshi Suzuki, Atsushi Shinagawa, Toshiki Uchida, et al.
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study]Kiyoshi Ando, Takaaki Chou, Kenshi Suzuki, et al.
Cancer Medicine|April 27, 2023
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasiaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
Haematologica|April 14, 2022
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphomaNorio Tanaka, Seiichi Mori, Kazuma Kiyotani, et al.
Journal of Cancer|May 7, 2014
Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsYumiko Sato, Masahiro Kondo, Atsushi Inagaki, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Leukemia Research|November 12, 2013
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaAtsushi Inagaki, Emi Tajima, Miyuki Uranishi, et al.
Pageof 29

Showing results (241-250 of 290) with videos related to

Sort By:
Pageof 29
Cancer Science|September 25, 2020
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy studyKazutaka Sunami, Kenshi Suzuki, Masaki Ri, et al.
Cancer Science|February 26, 2016
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II studyKenshi Suzuki, Atsushi Shinagawa, Toshiki Uchida, et al.
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study]Kiyoshi Ando, Takaaki Chou, Kenshi Suzuki, et al.
Cancer Medicine|April 27, 2023
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasiaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
Haematologica|April 14, 2022
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphomaNorio Tanaka, Seiichi Mori, Kazuma Kiyotani, et al.
Journal of Cancer|May 7, 2014
Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsYumiko Sato, Masahiro Kondo, Atsushi Inagaki, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Leukemia Research|November 12, 2013
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaAtsushi Inagaki, Emi Tajima, Miyuki Uranishi, et al.
Pageof 29